Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy.

Angiogenesis and co-optive vascular remodeling are prerequisites of solid tumor growth. Vascular heterogeneity, notably perivascular composition, may play a critical role in determining the rate of cancer progression. The contribution of vascular pericyte heterogeneity to cancer progression and therapy response is unknown. Here, we show that angiopoietin-2 (Ang2) orchestrates pericyte heterogeneity in breast cancer with an effect on metastatic disease and response to chemotherapy. Using multispectral imaging of human breast tumor specimens, we report that perivascular composition, as defined by the ratio of PDGFRβ- and desmin+ pericytes, provides information about the response to epirubicin but not paclitaxel. Using 17 distinct patient-derived breast cancer xenografts, we demonstrate a cancer cell-derived influence on stromal Ang2 production and a cancer cell-defined control over tumor vasculature and perivascular heterogeneity. The aggressive features of tumors and their distinct response to therapies may thus emerge by the cancer cell-defined engagement of distinct and heterogeneous angiogenic programs.

[1]  Rakesh K. Jain,et al.  Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients , 2015, Proceedings of the National Academy of Sciences.

[2]  M. Senchukova,et al.  Different types of tumor vessels in breast cancer: morphology and clinical value , 2015, SpringerPlus.

[3]  G. Mills,et al.  Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes , 2015, PloS one.

[4]  T. Aas,et al.  Concomitant inactivation of the p53‐ and pRB‐ functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo , 2015, Molecular oncology.

[5]  Steffen Dickopf,et al.  A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis , 2015, Nature.

[6]  R. Kalluri,et al.  Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2. , 2015, Cell reports.

[7]  K. Alitalo,et al.  Endothelial destabilization by angiopoietin-2 via integrin β1 activation , 2015, Nature Communications.

[8]  Kshitij Srivastava,et al.  Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. , 2014, Cancer cell.

[9]  I. Keklikoglou,et al.  Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. , 2014, Cell reports.

[10]  T. Aas,et al.  TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy , 2014, Acta oncologica.

[11]  H. Nakshatri,et al.  Angiopoietin‐2 mediates blood–brain barrier impairment and colonization of triple‐negative breast cancer cells in brain , 2014, The Journal of pathology.

[12]  Michele De Palma,et al.  A role for angiopoietin-2 in organ-specific metastasis. , 2013, Cell reports.

[13]  Li Yang,et al.  Perfusion Heterogeneity in Breast Tumors for Assessment of Angiogenesis , 2013, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[14]  P. Saharinen,et al.  Angiopoietin signaling in the vasculature. , 2013, Experimental cell research.

[15]  Dai Fukumura,et al.  Vascular normalization as an emerging strategy to enhance cancer immunotherapy. , 2013, Cancer research.

[16]  H. Augustin,et al.  Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. , 2013, Cancer research.

[17]  R. Danesi,et al.  The pharmacological bases of the antiangiogenic activity of paclitaxel , 2013, Angiogenesis.

[18]  Y. Kienast,et al.  A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors , 2013, PloS one.

[19]  K. Gelmon,et al.  Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. , 2012, Cancer treatment reviews.

[20]  Tetsuhiro Tanaka,et al.  Anthracycline Inhibits Recruitment of Hypoxia-inducible Transcription Factors and Suppresses Tumor Cell Migration and Cardiac Angiogenic Response in the Host* , 2012, The Journal of Biological Chemistry.

[21]  F. Pépin,et al.  Gene-expression profiling of microdissected breast cancer microvasculature identifies distinct tumor vascular subtypes , 2012, Breast Cancer Research.

[22]  M. Felcht,et al.  Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. , 2012, The Journal of clinical investigation.

[23]  K. Alitalo,et al.  Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis , 2012, Journal of the National Cancer Institute.

[24]  Tanja Fehm,et al.  Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. , 2012, The New England journal of medicine.

[25]  Zainab N. Khan,et al.  Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. , 2012, Cancer cell.

[26]  C. Betsholtz,et al.  Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. , 2011, Developmental cell.

[27]  X. Yao,et al.  Angiopoietin-2, an Angiogenic Regulator, Promotes Initial Growth and Survival of Breast Cancer Metastases to the Lung through the Integrin-linked Kinase (ILK)-AKT-B Cell Lymphoma 2 (Bcl-2) Pathway* , 2011, The Journal of Biological Chemistry.

[28]  L. Naldini,et al.  Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis , 2011, Clinical Cancer Research.

[29]  T. Aas,et al.  Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel , 2011, PloS one.

[30]  L. Naldini,et al.  Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. , 2011, Cancer cell.

[31]  K. Plate,et al.  Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion , 2011, The Journal of Immunology.

[32]  B. Coomber,et al.  Heterogeneity of vascular and progenitor cell compartments in tumours from MMTV‐PyVmT transgenic mice during mammary cancer progression , 2011, International journal of experimental pathology.

[33]  A. Raza,et al.  Pericytes and vessel maturation during tumor angiogenesis and metastasis , 2010, American journal of hematology.

[34]  K. Plate,et al.  Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. , 2010, Cancer research.

[35]  T. Tahir,et al.  Effects of angiopoietins-1 and -2 on the receptor tyrosine kinase Tie2 are differentially regulated at the endothelial cell surface , 2010, Cellular signalling.

[36]  R. Jain.  A new target for tumor therapy. , 2009, The New England journal of medicine.

[37]  Markus Thomas,et al.  The role of the Angiopoietins in vascular morphogenesis , 2009, Angiogenesis.

[38]  Gavin Thurston,et al.  Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system , 2009, Nature Reviews Molecular Cell Biology.

[39]  Jun O. Liu,et al.  Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells , 2009, Proceedings of the National Academy of Sciences.

[40]  Steinar Lundgren,et al.  CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer , 2008, PloS one.

[41]  Lauri Eklund,et al.  Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell–cell and cell–matrix contacts , 2008, Nature Cell Biology.

[42]  Holger Gerhardt,et al.  Pericytes: gatekeepers in tumour cell metastasis? , 2008, Journal of Molecular Medicine.

[43]  M. J. Jarzynka,et al.  Angiopoietin-2 Stimulates Breast Cancer Metastasis through the α5β1 Integrin-Mediated Pathway , 2007 .

[44]  D. Edelman,et al.  Pericytes and their role in microvasculature homeostasis. , 2006, The Journal of surgical research.

[45]  M. Mori,et al.  Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density , 2006, Breast Cancer Research and Treatment.

[46]  C. Betsholtz,et al.  Pericytes and vascular stability. , 2006, Experimental cell research.

[47]  Holger Gerhardt,et al.  Pericytes limit tumor cell metastasis. , 2006, The Journal of clinical investigation.

[48]  H. Augustin,et al.  The Tie-2 ligand Angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism , 2005, Journal of Cell Science.

[49]  H. Augustin,et al.  Expression of Angiopoietin-2 in Endothelial Cells Is Controlled by Positive and Negative Regulatory Promoter Elements , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[50]  H. Augustin,et al.  The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. , 2004, Blood.

[51]  P. Sismondi,et al.  Angiopoietin‐2 expression in breast cancer correlates with lymph node invasion and short survival , 2003, International journal of cancer.

[52]  P. Campochiaro,et al.  Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. , 2002, Developmental cell.

[53]  R. Kerbel,et al.  'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. , 2000, European journal of cancer.

[54]  H. Augustin,et al.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.

[55]  Lei Deng,et al.  Pericytes: a double-edged sword in cancer therapy. , 2015, Future oncology.

[56]  Ping Li,et al.  Diagnostic and prognostic potential of serum angiopoietin-2 expression in human breast cancer. , 2015, International journal of clinical and experimental pathology.

[57]  D. Berry,et al.  Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  Wei Liu,et al.  Targeted genes and interacting proteins of hypoxia inducible factor-1. , 2012, International journal of biochemistry and molecular biology.